Tony Baldinelli

Mr. Speaker, it is an honour for me to rise in my place today to participate in the debate on our opposition motion, which calls on the federal government to support the Conservative plan to double automotive production through a tariff-free auto pact. This bold new policy offers a fresh take on a similar policy, embodied by the old auto pact rules that resulted in Canada's auto manufacturing [more]

Mr. Speaker, there is the notion that Stellantis's failure is partly to be blamed on the government and its failed EV policies. Again, Stellantis has written off $27 billion because of this fallacy of an EV mandate that the Liberals have put in place instead of recognizing that the market should determine what the sales levels in autos should be. Why not go back? We met with Unifor today, and [more]

Mr. Speaker, what we do not support is the Liberals' failed EV policy, which they are implementing. They fail to realize that 90% of the autos that are produced in this country are shipped to the United States. The success of the auto industry in Canada was based on the regulatory harmony that existed with our largest trading partner and customer for Canadian-made autos, the United States. The [more]

Mr. Speaker, through our policy on this Canadian auto pact, we are talking about a policy to buy Canadian, sell here and build here. It only makes sense. We want to encourage those who want to produce, such as the big three automakers. General Motors has been in my community since 1929. They have invested and grown with this community. They have been in this community for almost 100 years. I [more]

To your point, the role the organization plays is filling an important gap that exists in the system. The research is being done. The federal government is committing the research through the CIHR, for example. They're doing the health research, but it's getting to the next stage, that clinical trial. Again, are we investing those critical dollars? Are they reaching the patient? Do you not think [more]

That's a key term, the opportunity cost. Dr. Michaud, you questioned whether the investment is reaching the patient. When those contribution agreements are signed, does your organization then go forward and present business plans for the government that transcend that period of time? Now the government is asking you to make last-minute changes to those agreements. You're well into your plans. [more]

Thank you, Madam Chair, and thank you to the witnesses for being with us this afternoon. I'm going to begin with Dr. Michaud. I enjoyed your presentation. With regard to BioCanRx, in your remarks, you said, “progress is real” and it leads to “real-world outcomes”. You said that we need to harness our scientific strengths for our overall sovereignty. Ultimately, the question that we need to ask [more]

Thank you, Madam Chair Thank you to the witnesses. Mr. Doyle, it's good to see you again. Thank you for being here. I've always appreciated the applied research side of our scientific research and the funding of colleges. Niagara College in my community is the number one research college in all of Canada, and the work that Tech-Access does is critically important. You say you deal with 6,000 [more]

Last, on Friday night they're going to be celebrating the 10th anniversary of SONAMI, the Southern Ontario Network for Advanced Manufacturing Innovation. Niagara College is a lead on this. My colleague would like to know that McMaster University is the only university amongst the colleges that participate. They do fabulous work in working with government, not only on the research side, but with [more]

Thank you.

At the same time, should the government invest and that person leave the country, taking that IP with them, should those dollars we've invested into that corporation then come back to the taxpayers?